Home › Funds › Ikarian Capital, LLC › MNPR

Ikarian Capital, LLC position in MNPR

MONOPAR THERAPEUTICS INC · Health Care

Ikarian Capital, LLC reported holding 86,761 shares of MNPR (MONOPAR THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.9M, representing 1.01% of its reported portfolio and ranking #24 among its reported holdings. Ikarian Capital, LLC has disclosed MNPR holdings in 4 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)86.76K sh
Reported value held$6.91M
Portfolio Weight1.01%
First reportedQ4 2024
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Ikarian Capital, LLC's MNPR position evolved

Ikarian Capital, LLC first disclosed a stake in MNPR in Q4 2024 at 5,908 shares (US$130K). The position peaked in Q3 2026 at 86,761 shares, worth US$6.9M. Across 4 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 86,761 shares valued at US$6.9M — an increase of 38,900 shares quarter over quarter.. Notable position changes include a 81% increase in Q3 2026 (shares fell 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 5.91K $129.98K New
Q1 2025 5.91K $215.11K Hold
Q2 2026 47.86K $4.43M New
Q3 2026 86.76K $6.91M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MNPR and 13F data

MNPR (MONOPAR THERAPEUTICS INC) is a Health Care company. 69 other funds we track also report a position in MNPR — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$53.2M), Saturn V Capital Management LP (US$24.9M), Siren, L.L.C. (US$21.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MNPR

All MNPR fund holders →

FAQ

How long has Ikarian Capital, LLC held MNPR?

Ikarian Capital, LLC has disclosed MNPR holdings in 4 of the last 8 reported quarters, going back to Q4 2024.

What is Ikarian Capital, LLC's current position in MNPR?

As of Q3 2026, Ikarian Capital, LLC holds 86.76K shares of MNPR (MONOPAR THERAPEUTICS INC), valued at $6.91M, representing 1.01% of its reported portfolio and ranking #24.

Has Ikarian Capital, LLC been buying or selling MNPR?

In the latest 13F filing (Q3 2026), Ikarian Capital, LLC increased its position in MNPR. The position peaked in Q3 2026 at 86.76K shares.

Which other funds hold MNPR?

Other major institutional holders of MNPR include RA CAPITAL MANAGEMENT, L.P., Saturn V Capital Management LP, Siren, L.L.C., among 69 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.